Internationally, Emcure has built strong front-end capabilities through a well-executed acquisition-led strategy in Canada and Europe, while maintaining a vertically integrated supply chain through its Indian manufacturing base

Pune headquartered Emcure Pharmaceuticals is a diversified pharma player focused on developing, manufacturing and marketing a broad range of pharmaceutical products in the domestic/international markets.

Emcure’s domestic business combines a strong position in chronic and acute therapies, leadership in Women ’s care, a sizeable Injectables franchise and a differentiated front-end platform through Zuventus. Importantly, the company has multiple relatively low-risk growth opportunities through strategic in-licensing partnerships with global innovators, providing access to established products and emerging therapy areas without incurring significant R&D investments. The GLP -1 opportunity, expansion into MASH, Ophthalmics, Dermatology and Consumer Health provide additional optionality beyond the core portfolio.

Internationally, Emcure has built strong front-end capabilities through a well-executed acquisition-led strategy in Canada and Europe, while maintaining a vertically integrated supply chain through its Indian manufacturing base. Its large and diversified product pipeline, presence in complex generics and differentiated opportunities such as Semaglutide, Liposomal Amphotericin B and Lenacapavir strengthen medium-term growth visibility. 

The combination of a diversified domestic franchise, scalable international platforms, proven M&A execution and multiple complex -product opportunities offer a stronger and more diversified growth profile. 

We value Emcure Pharma at ₹2,305 per share, based on 30x FY28E EPS of ₹76.8.

Copyright© 2026, THG PUBLISHING PVT LTD. or its affiliated companies. All rights reserved.

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Source: Read the original article on www.thehindubusinessline.com